RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function
Sponsor: Eurofins Optimed
Terminated
Due to other phase 3 trial failure to meet primary endpoint
Other terminated trials from Eurofins Optimed
More terminations from Eurofins Optimed
Listed as NCT04252430, this PHASE1 trial focuses on Healthy Volunteers and Impaired Renal Function and remains terminated or withdrawn. Sponsored by Eurofins Optimed, it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE1
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eurofins Optimed
- MedDay Pharmaceuticals SA
For direct contact, visit the study record on ClinicalTrials.gov .